Tirzepatide emerges a groundbreaking treatment agent for individuals battling type 2 diabetes. As a dual agonist, it targets both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide https://susanwvet687616.bloggazza.com/39334257/tirzepatide-a-novel-glp-1-and-gip-receptor-agonist